Texas Retina Associates

Summary

Texas Retina Associates is a medical facility located in Lubbock, Texas. This center is recognized for care of Diabetic Macular Edema, Diabetic Retinopathy, Edema, Macular Degeneration, Vitreous Hemorrhage and other specialties. Texas Retina Associates is involved with conducting 21 clinical trials across 14 conditions. There are 1 research doctors associated with this hospital, such as Michel Shami, MD.

Top PIs

Clinical Trials running at Texas Retina Associates

Diabetic Retinopathy

Macular Pucker

Macular Degeneration

Visual Impairment

Radiation Retinopathy

Blindness

Faricimab + PRP vs. Vitrectomy + Endolaser

for Diabetic Retinopathy

This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.

Recruiting

2 awards

Phase 3

3 criteria

Fenofibrate

for Diabetic Retinopathy

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the drug safely. If this study demonstrates that fenofibrate is effective for reducing the onset of proliferative diabetic retinopathy (PDR) or and the results are adopted by the community of retina specialists, a new strategy to prevent vision threatening complications of diabetes could be widely adopted. Widespread use of an oral agent effective at reducing worsening of DR would decrease the numbers of patients who undergo more invasive and much more expensive treatment for DR and who are consequently at risk for side effects that adversely affect visual function. This study will also assess the relationship of glycemic variability, as measured by continuous glucose monitoring with DR outcomes. Ancillary studies will characterize functional and structural outcomes in this cohort.

Recruiting

1 award

Phase 3

5 criteria